» Articles » PMID: 27397923

Effects of Sublingual Immunotherapy in a Murine Asthma Model Sensitized by Intranasal Administration of House Dust Mite Extracts

Overview
Journal Allergol Int
Publisher Elsevier
Date 2016 Jul 12
PMID 27397923
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sublingual immunotherapy (SLIT) has received attention as a method for allergen immunotherapy. However, the mechanism of SLIT has not yet been fully investigated. Therefore, we evaluated the effects of SLIT in a murine asthma model, sensitized by intranasal administration of house dust mite (HDM) extracts.

Methods: Female BALB/c mice were intranasally exposed to HDM for either 3 or 5 weeks (5 consecutive days per week). Mice were administered either low-dose (0.5 mg/day) or high-dose (5 mg/day) sublingual HDM extracts for 2 weeks, followed by an additional week of intranasal exposure. Airway hyperresponsiveness (AHR), bronchoalveolar lavage fluid (BALF) cell count, cytokine levels in the BALF and lymph node cell culture supernatants, and allergen-specific antibodies were measured. Lung histology was also investigated.

Results: In mice sensitized for 5 weeks, high-dose SLIT ameliorated AHR, airway eosinophilia and goblet cell metaplasia. In mice sensitized for 3 weeks, even low dose SLIT ameliorated AHR and airway eosinophilia. Th2 cytokine levels in culture supernatants of submandibular lymph node cells in high-dose SLIT mice decreased, whereas IL-10 levels increased. Total IgA in BALF increased in mice sensitized for 3 or 5 weeks, and high-dose SLIT also increased allergen-specific IgG2a in mice sensitized for 5 weeks.

Conclusions: These data suggest that earlier induction of SLIT in HDM-sensitized mice provides superior suppression of AHR and goblet cell metaplasia. The modulation of allergen specific IgG2a and local IgA might play a role in the amelioration of AHR and airway inflammation.

Citing Articles

Adjuvant Effect of in Sublingual Immunotherapy of Asthmatic Mice.

Alwayli D, Jiang X, Liang J, Shah S, Ullah A, Abusidu M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770422 PMC: 11678203. DOI: 10.3390/ph17121580.


Mechanism differences in the start time of sublingual immunotherapy in a mouse allergic airway inflammation model.

Saito A, Koya T, Aoki A, Naramoto S, Ueno H, Nishiyama Y Sci Rep. 2024; 14(1):26334.

PMID: 39487347 PMC: 11530651. DOI: 10.1038/s41598-024-78062-6.


Immune mechanisms induced by sublingual immunotherapy in allergic respiratory diseases.

Gazi U, Bahceciler N Clin Exp Immunol. 2022; 209(3):262-269.

PMID: 35975953 PMC: 9521660. DOI: 10.1093/cei/uxac075.


CD44 is critical for the enhancing effect of hyaluronan in allergen-specific sublingual immunotherapy in a murine model of chronic asthma.

Katoh S, Uesaka T, Tanaka H, Matsuhara H, Ohashi-Doi K, Oga T Clin Exp Immunol. 2022; 208(2):202-211.

PMID: 35429379 PMC: 9188352. DOI: 10.1093/cei/uxac024.


Effects of β2-adrenergic agonists on house dust mite-induced adhesion, superoxide anion generation, and degranulation of human eosinophils.

Ueda Y, Nakagome K, Kobayashi T, Noguchi T, Soma T, Ohashi-Doi K Asia Pac Allergy. 2020; 10(2):e15.

PMID: 32411580 PMC: 7203437. DOI: 10.5415/apallergy.2020.10.e15.